Stock INZY INOZYME PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
4.58 USD -1.51% Intraday chart for Inozyme Pharma, Inc. -12.26% +7.51%
Apr. 08 Transcript : Inozyme Pharma, Inc. - Special Call
Apr. 08 Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency CI

Business Summary

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

Number of employees: 59

Managers

Managers TitleAgeSince
Axel Bolte FOU
 Founder 52 15-08-31
Doug Treco Treco CEO
 Chief Executive Officer 66 20-04-30
Sanjay Subramanian DFI
 Director of Finance/CFO 48 22-03-30
Yves Sabbagh CTO
 Chief Tech/Sci/R&D Officer - 20-10-12
David Thompson CTO
 Chief Tech/Sci/R&D Officer - 18-03-31
Matthew Winton COO
 Chief Operating Officer 46 23-03-31
Soo-Jin Kim CTO
 Chief Tech/Sci/R&D Officer - 22-03-07
Kurt C. Gunter CTO
 Chief Tech/Sci/R&D Officer 69 22-06-06
Stefan Riley IRC
 Investor Relations Contact - -
Gayle Gironda HRO
 Human Resources Officer - 21-07-12

Members of the board

Members of the board TitleAgeSince
Doug Treco Treco CEO
 Chief Executive Officer 66 20-04-30
Reinaldo Diaz BRD
 Director/Board Member 70 16-12-31
Axel Bolte FOU
 Founder 52 15-08-31
Ed Mathers Mathers BRD
 Director/Board Member 64 16-12-31
Martin Edwards BRD
 Director/Board Member 68 17-08-31
Robert Hopfner BRD
 Director/Board Member 51 18-10-31
Lynne Sullivan BRD
 Director/Board Member 58 20-04-30
Sarah Bhagat BRD
 Director/Board Member 38 19-02-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,771,977 61,366,254 ( 99.34 %) 0 99.34 %

Shareholders

NameEquities%Valuation
Longitude Capital Management Co LLC
9.456 %
5,841,045 9.456 % 45 M $
Adage Capital Partners GP LLC
8.964 %
5,537,500 8.964 % 42 M $
Pivotal Bioventure Partners Investment Advisor LLC
7.277 %
4,494,851 7.277 % 34 M $
Sofinnova Investments, Inc.
6.929 %
4,280,308 6.929 % 33 M $
Rock Springs Capital Management LP
5.959 %
3,681,174 5.959 % 28 M $
Samlyn Capital LLC
5.460 %
3,372,558 5.460 % 26 M $
Eventide Asset Management LLC
5.148 %
3,179,837 5.148 % 24 M $
BlackRock Advisors LLC
4.709 %
2,908,808 4.709 % 22 M $
NEA Management Co. LLC
3.946 %
2,437,689 3.946 % 19 M $
Vanguard Fiduciary Trust Co.
3.861 %
2,385,022 3.861 % 18 M $

Company contact information

Inozyme Pharma, Inc.

321 Summer Street Suite 400

02210, Boston

+

http://www.inozyme.com
address Inozyme Pharma, Inc.(INZY)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.58 USD
Average target price
20.33 USD
Spread / Average Target
+343.96%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INOZYME PHARMA, INC. Stock Inozyme Pharma, Inc.
+7.51% 287M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.36B
LONZA GROUP AG Stock Lonza Group AG
+44.25% 41.3B
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 25.62B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.38B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.85B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.82B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. INZY Stock
  4. Company Inozyme Pharma, Inc.